Clinical Trial Update: An Open-label Extension Study of PSMA ADC 2301 in mCRPC [Phase 2]

View source ↗

Summary

An open-label extension study of PSMA ADC 2301 in metastatic castration-resistant prostate cancer (Phase 2) has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PSMA ADC 2301

Snippet

Sponsor: Progenics Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-02-23